1. What are the key recommendations for perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty according to the 2022 American College of Rheumatology guideline?
2. Why are all recommendations in the guideline considered conditional?
3. Which disease-modifying antirheumatic drugs (DMARDs) are conditionally recommended to be continued through surgery for patients with RA, AS, PsA, JIA, or SLE undergoing elective THA or TKA?
4. What is the recommendation for withholding biologics, including rituximab, prior to surgery for patients with RA, AS, PsA, or JIA undergoing elective THA or TKA?
5. How should glucocorticoid therapy be managed for patients with RA, AS, PsA, or SLE undergoing THA or TKA?
6. What is the updated recommendation for withholding tofacitinib, baricitinib, and upadacitinib prior to surgery for patients with RA, AS, PsA, or JIA undergoing THA or TKA?
7. What medications are conditionally recommended to be withheld for patients with SLE (not severe) undergoing THA or TKA?
8. What is the recommendation for patients with severe SLE undergoing THA or TKA regarding the continuation of belimumab and rituximab?
9. When should antirheumatic therapy be restarted for patients with RA, AS, PsA, or SLE who underwent total joint arthroplasty?
10. What is the recommendation for managing glucocorticoid therapy on the day of surgery for patients with RA, AS, PsA, or SLE undergoing THA or TKA?